超声引导单次竖脊肌平面阻滞用于胸腔镜楔形切除术的疗效:前瞻性随机对照试验
主要结局术后第1天QoR-40评分两组无差异(169.5 vs 172.5,p=0.843),除罗哌卡因组术后1小时VAS评分较低和PACU停留时间缩短117分钟外,其余次要结局均无显著差异。结论认为在标准多模式镇痛基础上加用罗哌卡因ESP阻滞不太可能增加有意义的临床价值。
要点
- VATS楔形切除术后,ESP阻滞未改善术后第1天QoR-40评分。
- 罗哌卡因组术后1小时VAS疼痛评分较低,PACU停留时间缩短117分钟。
- 在标准多模式镇痛基础上加用ESP阻滞未显示有意义的临床获益。
核心结论
- VATS楔形切除术后,在标准多模式镇痛基础上加用罗哌卡因ESP阻滞不太可能增加有意义的临床价值。
研究设计与样本
- 前瞻性、随机、安慰剂对照、双盲研究,在三级胸外科中心开展。
- 连续接受VATS楔形切除术的患者随机接受0.5%罗哌卡因或0.9%盐水单次ESP阻滞,均联合标准多模式镇痛(包括患者自控镇痛和手术局部麻醉药伤口浸润)。
主要发现
- 术后第1天QoR-40中位数评分两组无差异:罗哌卡因组169.5,对照组172.5(差值3,p=0.843)。
- 除罗哌卡因组术后1小时VAS疼痛评分较低和PACU停留时间缩短117分钟外,其余次要结局两组均无显著差异。
临床怎么用
- 对于VATS楔形切除术患者,在标准多模式镇痛基础上加用单次罗哌卡因ESP阻滞对术后恢复质量无显著改善,临床决策时可考虑其有限获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advances in minimally invasive thoracic surgery, patients remain at risk of adverse pulmonary events with suboptimal postoperative analgesia. Novel methods of regional analgesia are warranted. Our objective was to prospectively evaluate the impact of ultrasound-guided single-injection erector spinae plane (ESP) block with ropivacaine compared with placebo control on standard of care postoperative recovery in subjects undergoing video-assisted thoracoscopic surgery (VATS) wedge resection. METHODS: This prospective, randomized, placebo-controlled, double-blinded study was conducted at a tertiary thoracic surgical center. Consecutive subjects undergoing VATS wedge resection were randomized to receive a single-injection ESP block with 0.5% ropivacaine or 0.9% saline placebo, in addition to the current standard of care of multimodal analgesia including patient-controlled analgesia and surgical local anesthetic wound infiltration. The primary outcome was difference in 40-point Quality of Recovery (QoR-40) on day 1 postoperatively. The secondary outcomes included opioid consumption, Visual Analog Pain Scale (VAS) score, time spent in the postanesthesia care unit (PACU), and block-related and postoperative complications. RESULTS: Eighty subjects were enrolled, 40 in each group, with 76 completing follow-up (38 subjects in each group). There was no difference in the median QoR-40 score between groups, 169.5 for the ropivacaine group and 172.5 for the control group (difference 3, p=0.843). No significant differences existed between groups in all secondary outcomes, with the exception of the ropivacaine group having lower VAS pain scores measured at 1 hour postoperatively and a shorter duration of stay in the PACU of 117 min. CONCLUSIONS: Following VATS wedge resection, the addition of an ESP block with ropivacaine to standard multimodal analgesia is unlikely to add meaningful clinical value. TRIAL REGISTRATION NUMBER: NCT03419117.
引用
- Klaibert B, Lohser J, Tang R, et al. Efficacy of ultrasound-guided single-injection erector spinae plane block for thoracoscopic wedge resection: a prospective randomized control trial. Reg Anesth Pain Med. 2022. PMID: 36150741. doi:10.1136/rapm-2022-103602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。